Abbott gets nod from DCGI for once-a-day formulation ‘Ivabradine’
3rd Sep 2020

Abbott has received approval from the Drugs Controller General of India (DCGI) for its once-a-day formulation, Ivabradine, used for treatment of chronic heart failure and chronic stable angina. The company plans to launch Ivabradine prolonged release tablets in the Indian market in the coming weeks.

Abbott India is healthcare company that discovers, develops, manufactures and markets innovative products and services.